Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Rapid correction of low vitamin D status in nursing home residents 3. 2008 Exclusive Survey—Earnings: Good news for primary care income 4. Medicare pay-for-reporting effort draws fire from frustrated doctors 5. Allopurinol-induced recurrent dress syndrome: Pathophysiology and treatment
Top Ten Searches
rheumatoid arthritis lupus polymyalgia sjogrens fibromyalgia amyloidosis vasculitis urate raynauds myositisYour Article Summary
See Latest ArticlesTargeting interleukin-6 in pediatric rheumatic diseases
Current Opinion in Rheumatology, 08/18/09
De Benedetti F – Study reports that targeting IL-6 activities is an effective approach in the treatment of chronic inflammatory diseases. The long-term benefit and safety of tocilizumab have to be defined in long-term extension studies; the risk/benefit ratio appears to be particularly favorable in systemic juvenile idiopathic arthritis (s-JIA).
Methods- Main objectives of this study were to:
- Describe the most recent data regarding the role of IL-6 in immune and inflammatory responses
- Mode of action and safety information on tocilizumab, the only available IL-6 inhibitor, and
- Discuss recent results on the therapeutic inhibition of IL-6 in pediatric rheumatic diseases
- New data on the effects of IL-6 on T and B cells are available
- Clinical trials with tocilizumab in adults provide new data on mechanism of action particularly in RA, and safety database
- A withdrawal design trial showed marked efficacy in s-JIA
- Open label studies or anecdotal reports suggest possible efficacy also in other JIA subtypes, as well as other rheumatic diseases
Related Articles
Will treatment of rheumatoid arthritis with an IL-6R inhibitor help facilitate the age of remission?
Expert Opinion on Investigational Drugs, 10/13/09
Relevance Score: 78%
Minimal influence of tocilizumab on IFN-gamma synthesis by tuberculosis antigen
Modern Rheumatology, 11/17/09
Relevance Score: 66%
Switching to the anti-interleukin-6 receptor antibody tocilizumab in rheumatoid arthritis patients refractory to antitumor necrosis factor biologics
Modern Rheumatology, 10/08/09
Relevance Score: 66%
Improving the management of paediatric rheumatic diseases globally
Best Practice & Research: Clinical Rheumatology, 10/28/09
Relevance Score: 65%
Proinflammatory cytokines synergistically enhance the production of chemokine ligand 20 (CCL20) from rheumatoid fibroblast-like synovial cells in vitro and serum CCL20 is reduced in vivo by biologic disease-modifying antirheumatic drugs
Journal of Rheumatology, 10/05/09
Relevance Score: 65%
Today in Pediatric Rheumatology...keeping you current
Receive free subspecialty "5-minute updates" via email
Environmental factors and the geoepidemiology of juvenile idiopathic arthritis
Autoimmunity Reviews, 03/18/10
Pediatric Pigmented Villonodular Synovitis Mimicking a Septic Hip
Journal of Clinical Rheumatology (JCR), 03/16/10
Osteomyelitis of the scapula with secondary septic arthritis of the shoulder joint
Singapore Medical Journal, 03/12/10
Today in Rheumatoid Arthritis...keeping you current
Receive free subspecialty "5-minute updates" via email
New low-field extremity MRI, compacTscan: comparison with whole-body 1.5 T conventional MRI
Modern Rheumatology, 03/18/10
Safety and efficacy profiles of tocilizumab monotherapy in Japanese patients with rheumatoid arthritis: meta-analysis of six initial trials and five long-term extensions
Modern Rheumatology, 03/18/10
Decreased circulating CD28-negative T cells in patients with rheumatoid arthritis treated with abatacept are correlated with clinical response
Journal of Rheumatology, 03/18/10
Sponsor
Article Search
Sponsor
Sponsor